Perivascular tissue resident memory T cells as therapeutic target in multiple sclerosis

References

• Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214–219.
   PubMed Web of Science ®Google Scholar
• Farh KKH, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518(7539):337–343.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636.
   PubMed Web of Science ®Google Scholar
• Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15(5):287–300.
   PubMed Web of Science ®Google Scholar
• Wong YYM, van der Vuurst de Vries RM, van Pelt ED, et al. T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes. Mult Scler J. 2018;24(13):1715–1724.
   PubMed Web of Science ®Google Scholar
• van der Vuurst de Vries RM, Mescheriakova JY, Runia TF, et al. Soluble CD27 levels in cerebrospinal fluid as a prognostic biomarker in clinically isolated syndrome. JAMA Neurol. 2017;74(3):286.
   PubMed Web of Science ®Google Scholar
• Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183–193.
   PubMed Web of Science ®Google Scholar
• Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–558.
   PubMed Web of Science ®Google Scholar
• Kuhlmann T, Ludwin S, Prat A, et al. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 2017;133(1):13–24.
   PubMed Web of Science ®Google Scholar
• Zrzavy T, Hametner S, Wimmer I, et al. Loss of “homeostatic” microglia and patterns of their activation in active multiple sclerosis. Brain. 2017;140:1900–1913.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74(6):659–674.
   PubMed Web of Science ®Google Scholar
• Jeffery DR, Rammohan KW, Hawker K, et al. Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis. Expert Rev Neurother. 2016;16(1):31–44.
   PubMed Web of Science ®Google Scholar
• Hoepner R, Faer S, Salmen A, et al. Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. J Cent Nerv Syst Dis. 2014;6:41–49.
   PubMedGoogle Scholar
• Giovannoni G. Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics. 2017;14(4):874–887.
   PubMed Web of Science ®Google Scholar
• Jones JL, Coles AJ. Mode of action and clinical studies with alemtuzumab. Exp Neurol. 2014;262(PartA):37–43.
   PubMedGoogle Scholar
• Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics. 2017;14(4):835–841.
   PubMed Web of Science ®Google Scholar
• Muraro PA, Martin R, Mancardi GL, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017;13(7):391–405.
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707–717.
   PubMed Web of Science ®Google Scholar
• Metz I, Weigand SD, Popescu BFG, et al. Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol. 2014;75(5):728–738.
   PubMed Web of Science ®Google Scholar
• Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med. 2001;7(3):115–121.
   PubMed Web of Science ®Google Scholar
• Breij ECW, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol. 2008;63(1):16–25.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology. 1992;42(1):60–63.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler J. 2015;21(8):1013–1024.
   PubMed Web of Science ®Google Scholar
• Plumb J, McQuaid S, Mirakhur M, et al. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol. 2002;12(2):154–169.
   PubMed Web of Science ®Google Scholar
• van Horssen J, Brink BP, de Vries HE, et al. The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol. 2007;66(4):321–328.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12(9):623–635.
   PubMed Web of Science ®Google Scholar
• Luchetti S, Fransen NL, van Eden CG, et al. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol. 2018;135(4):511–528.
   PubMed Web of Science ®Google Scholar
• Michailidou I, Naessens DMP, Hametner S, et al. Complement C3 on microglial clusters in multiple sclerosis occur in chronic but not acute disease: implication for disease pathogenesis. Glia. 2017;65(2):264–277.
   PubMed Web of Science ®Google Scholar
• Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. 2001;50(5):646–657.
   PubMed Web of Science ®Google Scholar
• Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain. 2006;129(Pt 12):3165–3172.
   PubMed Web of Science ®Google Scholar
• Melief J, De Wit SJ, Van Eden CG, et al. HPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matter. Acta Neuropathol. 2013;126(2):237–249.
   PubMed Web of Science ®Google Scholar
• Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710–721.
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Popescu BFG, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365(23):2188–2197.
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(11):2705–2712.
   PubMed Web of Science ®Google Scholar
• Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain. 2012;135(Pt 10):2925–2937.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(Pt 4):1089–1104.
   PubMed Web of Science ®Google Scholar
• Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134(Pt 9):2755–2771.
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14(2):164–174.
   PubMed Web of Science ®Google Scholar
• Fransen NL, Crusius JBA, Smolders J, et al. Post-mortem multiple sclerosis lesion pathology is influenced by single nucleotide polymorphisms. Brain Pathol. 2019 June;bpa.12760. DOI:10.1111/bpa.12760.
   PubMed Web of Science ®Google Scholar
• Smolders J, Remmerswaal EBM, Schuurman KG, et al. Characteristics of differentiated CD8+ and CD4+ T cells present in the human brain. Acta Neuropathol. 2013;126(4):525–535.
   PubMed Web of Science ®Google Scholar
• Smolders J, Heutinck KM, Fransen NL, et al. Tissue-resident memory T cells populate the human brain. Nat Commun. 2018;9(1):4593.
   PubMedGoogle Scholar
• Machado-Santos J, Saji E, Tröscher AR, et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain. 2018;141(7):2066–2082.
   PubMedGoogle Scholar
• Loeffler C, Dietz K, Schleich A, et al. Immune surveillance of the normal human CNS takes place in dependence of the locoregional blood-brain barrier configuration and is mainly performed by CD3+/CD8+ lymphocytes. Neuropathology. 2011;31(3):230–238.
   PubMed Web of Science ®Google Scholar
• Szabo PA, Miron M, Farber DL. Location, location, location: tissue resident memory T cells in mice and humans. Sci Immunol. 2019;4(34):eaas9673.
   PubMed Web of Science ®Google Scholar
• Mueller SN, Mackay LK. Tissue-resident memory T cells: local specialists in immune defence. Nat Rev Immunol. 2016;16(2):79–89.
   PubMed Web of Science ®Google Scholar
• Behr FM, Chuwonpad A, Stark R, et al. Armed and ready: transcriptional regulation of tissue-resident memory CD8 T cells. Front Immunol. 2018;9:1770.
   PubMed Web of Science ®Google Scholar
• Kumar BV, Ma W, Miron M, et al. Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep. 2017;20(12):2921–2934.
   PubMed Web of Science ®Google Scholar
• Mizee MR, Miedema SSM, van der Poel M, et al. Isolation of primary microglia from the human post-mortem brain: effects of ante- and post-mortem variables. Acta Neuropathol Commun. 2017;5(1):16.
   PubMedGoogle Scholar
• Wakim LM, Woodward-Davis A, Bevan MJ. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc Natl Acad Sci U S A. 2010;107(42):17872–17879.
   PubMed Web of Science ®Google Scholar
• Steinbach K, Vincenti I, Kreutzfeldt M, et al. Brain-resident memory T cells represent an autonomous cytotoxic barrier to viral infection. J Exp Med. 2016;213(8):1571–1587.
   PubMed Web of Science ®Google Scholar
• Shwetank, Frost EL, Mockus TE, et al. PD-1 dynamically regulates inflammation and development of brain-resident memory CD8 T cells during persistent viral encephalitis. Front Immunol. 2019;10:783.
   PubMed Web of Science ®Google Scholar
• Aguilar-Valenzuela R, Netland J, Seo Y-J, et al. Dynamics of tissue-specific CD8 + T cell responses during west nile virus infection. Dutch RE, ed. J Virol. 2018;92(10):e00014–18.
   PubMed Web of Science ®Google Scholar
• Schøller AS, Fonnes M, Nazerai L, et al. Local antigen encounter is essential for establishing persistent CD8+ T-cell memory in the CNS. Front Immunol. 2019;10:351.
   PubMed Web of Science ®Google Scholar
• de Graaf MT, Smitt PAES, Luitwieler RL, et al. Central memory CD4+ T cells dominate the normal cerebrospinal fluid. Cytom Part B Clin Cytom. 2011;80B(1):43–50.
   Web of Science ®Google Scholar
• Kivisäkk P, Mahad DJ, Callahan MK, et al. Human cerebrospinal fluid central memory CD4 + T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci. 2003;100(14):8389–8394.
   PubMed Web of Science ®Google Scholar
• Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol. 2010;10(10):712–723.
   PubMed Web of Science ®Google Scholar
• van Horssen J, Bö L, Vos CMP, et al. Basement membrane proteins in multiple sclerosis-associated inflammatory cuffs: potential role in influx and transport of leukocytes. J Neuropathol Exp Neurol. 2005;64(8):722–729.
   PubMed Web of Science ®Google Scholar
• Horng S, Therattil A, Moyon S, et al. Astrocytic tight junctions control inflammatory CNS lesion pathogenesis. J Clin Invest. 2017;127(8):3136–3151.
   PubMed Web of Science ®Google Scholar
• Plog BA, Nedergaard M. The glymphatic system in central nervous system health and disease: past, present, and future. Annu Rev Pathol Mech Dis. 2018;13(1):379–394.
   PubMedGoogle Scholar
• Faraco G, Park L, Anrather J, et al. Brain perivascular macrophages: characterization and functional roles in health and disease. J Mol Med. 2017;95(11):1143–1152.
   PubMed Web of Science ®Google Scholar
• Yang T, Guo R, Zhang F. Brain perivascular macrophages: recent advances and implications in health and diseases. CNS Neurosci Ther. 2019;25(12):1318–1328.
   PubMed Web of Science ®Google Scholar
• Topham DJ, Reilly EC. Tissue-resident memory CD8+ T cells: from phenotype to function. Front Immunol. 2018;9:515.
   PubMed Web of Science ®Google Scholar
• Fabriek BO, Van Haastert ES, Galea I, et al. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia. 2005;51(4):297–305.
   PubMed Web of Science ®Google Scholar
• Traugott U, Reinherz EL, Raine CS. Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J Neuroimmunol. 1983;4(3):201–221.
   PubMed Web of Science ®Google Scholar
• Fransen NL, Hsiao -C-C, van der Poel M, et al. Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions. Brain 2020;143(6):1714–1730.
   Google Scholar
• Revesz T, Kidd D, Thompson AJ, et al. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 1994;117(4):759–765.
   PubMedGoogle Scholar
• Guseo A, Jellinger K. The significance of perivascular infiltrations in multiple sclerosis. J Neurol. 1975;211(1):51–60.
   PubMed Web of Science ®Google Scholar
• Adams CWM. The onset and progression of the lesion in multiple sclerosis. J Neurol Sci. 1975;25(2):165–182.
   PubMed Web of Science ®Google Scholar
• Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(Pt 5):1175–1189.
   PubMed Web of Science ®Google Scholar
• Booss J, Esiri MM, Tourtellotte WW, et al. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci. 1983;62(1–3):219–232.
   PubMed Web of Science ®Google Scholar
• Babbe H, Roers A, Waisman A, et al. Clonal expansions of Cd8 + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000;192(3):393–404.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bhan AK, Gilles F, et al. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol. 1986;19(6):578–587.
   PubMed Web of Science ®Google Scholar
• Bitsch A. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain. 2000;123(6):1174–1183.
   PubMedGoogle Scholar
• Kuhlmann T. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 2002;125(10):2202–2212.
   PubMedGoogle Scholar
• van Nierop GP, van Luijn MM, Michels SS, et al. Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients. Acta Neuropathol. 2017;134(3):383–401.
   PubMed Web of Science ®Google Scholar
• Sørensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103(6):807–815.
   PubMed Web of Science ®Google Scholar
• Hendrickx DAE, Koning N, Schuurman KG, et al. Selective upregulation of scavenger receptors in and around demyelinating areas in multiple sclerosis. J Neuropathol Exp Neurol. 2013;72(2):106–118.
   PubMed Web of Science ®Google Scholar
• Schläger C, Körner H, Krueger M, et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature. 2016;530(7590):349–353.
   PubMed Web of Science ®Google Scholar
• Bell L, Lenhart A, Rosenwald A, et al. Lymphoid aggregates in the CNS of progressive multiple sclerosis patients lack regulatory T cells. Front Immunol. 2020;10:3090.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang ZY, Schittenhelm J, et al. Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains. J Neuroimmunol. 2011;237(1–2):73–79.
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 1985;314(6011):537–539.
   PubMed Web of Science ®Google Scholar
• Salou M, Garcia A, Michel L, et al. Expanded CD8 T-cell sharing between periphery and CNS in multiple sclerosis. Ann Clin Transl Neurol. 2015;2(6):609–622.
   PubMed Web of Science ®Google Scholar
• Chang G-W, Hsiao -C-C, Peng Y-M, et al. The adhesion G protein-coupled receptor GPR56/ADGRG1 is an inhibitory receptor on human NK cells. Cell Rep. 2016;15(8):1757–1770.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Serafini B, Rosicarelli B, et al. B-cell enrichment and epstein-barr virus infection in inflammatory cortical lesions in secondary Progressive multiple sclerosis. J Neuropathol Exp Neurol. 2013;72(1):29–41.
   PubMed Web of Science ®Google Scholar
• Konjevic Sabolek M, Held K, Beltrán E, et al. Communication of CD8 + T cells with mononuclear phagocytes in multiple sclerosis. Ann Clin Transl Neurol. 2019;6(7):1151–1164.
   PubMed Web of Science ®Google Scholar
• Herich S, Schneider-Hohendorf T, Rohlmann A, et al. Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. Brain. 2019September;142:3411–3427.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–220.
   PubMed Web of Science ®Google Scholar
• Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 2007;323(2):469–476.
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355–360.
   PubMed Web of Science ®Google Scholar
• Metz I, Lucchinetti CF, Openshaw H, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain. 2007;130(5):1254–1262.
   PubMedGoogle Scholar
• Park SL, Zaid A, Hor JL, et al. Local proliferation maintains a stable pool of tissue-resident memory T cells after antiviral recall responses article. Nat Immunol. 2018;19(2):183–191.
   PubMed Web of Science ®Google Scholar
• Conry RM, Sullivan JC, Nabors LB. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res. 2015;3(6):598–601.
   PubMed Web of Science ®Google Scholar
• Cao Y, Nylander A, Ramanan S, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology. 2016;86(16):1553–1556.
   PubMed Web of Science ®Google Scholar
• Gerdes LA, Held K, Beltrán E, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann Neurol. 2016;80(2):294–300.
   PubMed Web of Science ®Google Scholar
• Maurice C, Schneider R, Kiehl T-R, et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res. 2015;3(12):1299–1302.
   PubMed Web of Science ®Google Scholar
• Durães J, Coutinho I, Mariano A, et al. Demyelinating disease of the central nervous system associated with pembrolizumab treatment for metastatic melanoma. Mult Scler J. 2019;25(7):1005–1008.
   PubMed Web of Science ®Google Scholar
• Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med. 2019;380(17):1597–1605.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477–486.
   PubMed Web of Science ®Google Scholar
• Giacomini PS, Rozenberg A, Metz I, et al. Maraviroc and JC virus–associated immune reconstitution inflammatory syndrome. N Engl J Med. 2014;370(5):486.
   PubMed Web of Science ®Google Scholar
• Hodecker SC, Stürner KH, Becker V, et al. Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS. Neurol - Neuroimmunol Neuroinflammation. 2017;4(2):e325.
   PubMedGoogle Scholar
• Bsteh G, Auer M, Iglseder S, et al. Severe early natalizumab-associated PML in MS: effective control of PML-IRIS with maraviroc. Neurol - Neuroimmunol Neuroinflammation. 2017;4(2):e323.
   PubMedGoogle Scholar
• Wehr A, Baeck C, Ulmer F, et al. Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Alisi A, ed. PLoS One. 2014;9(11):e112327.
   PubMed Web of Science ®Google Scholar
• Mackay LK, Rahimpour A, Ma JZ, et al. The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin. Nat Immunol. 2013;14(12):1294–1301.
   PubMed Web of Science ®Google Scholar
• Sporici R, Issekutz TB. CXCR3 blockade inhibits T-cell migration into the CNS during EAE and prevents development of adoptively transferred, but not actively induced, disease. Eur J Immunol. 2010;40(10):2751–2761.
   PubMed Web of Science ®Google Scholar
• de Jong EK, de Haas AH, Brouwer N, et al. Expression of CXCL4 in microglia in vitro and in vivo and its possible signaling through CXCR3. J Neurochem. 2008;105(5):1726–1736.
   PubMed Web of Science ®Google Scholar
• Koper O, Kamińska J, Sawicki K, et al. CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration. Adv Clin Exp Med. 2018;27(6):849–856.
   PubMed Web of Science ®Google Scholar
• Lucas RM, Hughes AM, Lay M-LJ, et al. Epstein-Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(10):1142–1148.
   PubMed Web of Science ®Google Scholar
• van Nierop GP, Janssen M, Mitterreiter JG, et al. Intrathecal CD4 + and CD8 + T-cell responses to endogenously synthesized candidate disease-associated human autoantigens in multiple sclerosis patients. Eur J Immunol. 2016;46(2):347–353.
   PubMed Web of Science ®Google Scholar
• Jaquiéry E, Jilek S, Schluep M, et al. Intrathecal immune responses to EBV in early MS. Eur J Immunol. 2010;40(3):878–887.
   PubMed Web of Science ®Google Scholar
• Lossius A, Johansen JN, Vartdal F, et al. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells. Eur J Immunol. 2014;44(11):3439–3452.
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204(12):2899–2912.
   PubMed Web of Science ®Google Scholar
• Veroni C, Serafini B, Rosicarelli B, et al. Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis. J Neuroinflammation. 2018;15(1):18.
   PubMedGoogle Scholar
• Serafini B, Rosicarelli B, Veroni C, et al. Epstein-Barr virus-specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with virus-infected cells: clue for a virus-driven immunopathological mechanism. J Virol. 2019;93:24.
   Web of Science ®Google Scholar
• Willis SN, Stadelmann C, Rodig SJ, et al. Epstein–Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009;132(12):3318–3328.
   PubMedGoogle Scholar
• Peferoen LAN, Lamers F, Lodder LNR, et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain. 2010;133(5):e137–e137.
   PubMedGoogle Scholar
• Aloisi F, Serafini B, Magliozzi R, et al. Detection of Epstein–Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain. 2010;133(12):e157–e157.
   PubMedGoogle Scholar
• Leibovitch EC, Jacobson S. Evidence linking HHV-6 with multiple sclerosis: an update. Curr Opin Virol. 2014;9:127–133.
   PubMed Web of Science ®Google Scholar
• Van Horssen J, Van Der Pol S, Nijland P, et al. Human endogenous retrovirus W in brain lesions: rationale for targeted therapy in multiple sclerosis. Mult Scler Relat Disord. 2016;8:11–18.
   PubMed Web of Science ®Google Scholar
• Garrison KE, Jones RB, Meiklejohn DA, et al. T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog. 2007;3(11):e165.
   PubMed Web of Science ®Google Scholar
• Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925–933.
   PubMed Web of Science ®Google Scholar
• Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9(4):425–437.
   PubMed Web of Science ®Google Scholar
• Tan CS, Ellis LC, Wüthrich C, et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J Virol. 2010;84(18):9200–9209.
   PubMed Web of Science ®Google Scholar
• Elsner C, Dörries K. Evidence of human polyomavirus BK and JC infection in normal brain tissue. Virology. 1992;191(1):72–80.
   PubMed Web of Science ®Google Scholar
• White FA, Ishaq M, Stoner GL, et al. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol. 1992;66(10):5726–5734.
   PubMed Web of Science ®Google Scholar
• Brück W. Multiple sclerosis pathogenesis: what are the missing pieces? ECTRIMS Online Lib. 2019 Sep 12; 279488. [cited 2019 Oct 31]. Available from: https://onlinelibrary.ectrims-congress.eu/ectrims/2019/stockholm/279488/wolfgang.brck.multiple.sclerosis.pathogenesis.what.are.the.missing.pieces.html.
   Google Scholar
• Beltrán E, Gerdes LA, Hansen J, et al. Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. J Clin Invest. 2019September;129:4758–4768.
   Web of Science ®Google Scholar
• van der Poel M, Ulas T, Mizee MR, et al. Transcriptional profiling of human microglia reveals grey–white matter heterogeneity and multiple sclerosis-associated changes. Nat Commun. 2019;10(1):1139.
   PubMedGoogle Scholar